CEBPA Gene mutational status A complete screening using high-resolution melt curve analysis

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

RÁZGA Filip DVOŘÁKOVÁ Dana JURČEK Tomáš JEŽÍŠKOVÁ Ivana KŘÍSTKOVÁ Zlatuše MAYER Jiří

Year of publication 2009
Type Article in Periodical
Magazine / Source Molecular diagnosis and therapy
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords acute myeloid leukemia; CEBPA mutation
Description In recent years, several independent prognostic factors in cytogenetically normal acute myeloid leukemia (CN-AML) have been reported. Mutations or the expression levels of certatin genes have been often used as molecular markers for preidiction of a patients outcome or for evaluation of treatment outcome. One of them, the gene encoding CCAAT/enhanced binding protein alpha (CEBPA), plays an important role in myeloid differentiation and, whn mutated, confers a favorable prognosis for patients with CN-AML. Complete mutation screening of the CEBPA gene is therefore beneficial and requires fast, precise, and sensitive diagnostic tools. Thus, for routine diagnostics, we developed a screening method using high-resolution melt curve analysis prior to direct sequencing, where only positive samples (according to reference) are further sequenced. With this approach, all positive and negative patients were successfully distinguished, and the results obtained were in absolute concordance with the direct sequence analysis.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.